Exisulind Prior to Radical Prostatectomy
Completed · Phase 2
Conditions studied: Prostatic Neoplasms
In brief
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be followed for total of 2 months from the time of starting study drug.
Key facts
- Study ID
- NCT00166478
- Run by
- Mayo Clinic
- People needed
- 130
- Starts
- 2002-04-01
- Expected to finish
- 2007-10-01
- Last updated by the study team
- 2010-01-28
Who can join
Age: 40 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.